Corus Pharma
Seattle
About Corus Pharma
Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 501 – 1,000
- Total funding: $150.2M
- Funding stage: M&A
- Last round: Series Unknown (Apr 2006)
- Website: coruspharma.com
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/corus-pharma-2651541 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.